

Naoki Inui

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4609667/publications.pdf>

Version: 2024-02-01

233
papers

4,773
citations

126708

33
h-index

143772

57
g-index

248
all docs

248
docs citations

248
times ranked

5116
citing authors

#	ARTICLE	IF	CITATIONS
1	Increased serum cholesterol and long-chain fatty acid levels are associated with the efficacy of nivolumab in patients with non-small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 203-217.	2.0	16
2	Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE. <i>Journal of Clinical Oncology</i> , 2022, 40, 180-188.	0.8	21
3	Involvement of autophagy in exacerbation of eosinophilic airway inflammation in a murine model of obese asthma. <i>Autophagy</i> , 2022, 18, 2216-2228.	4.3	19
4	Marked, Lasting Disease Regression and Concomitantly Induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in a Patient With Lung Adenocarcinoma and Autoantibodies Receiving Atezolizumab Plus Chemotherapy: A Case Report. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100263.	0.6	3
5	EGFR-Mutated Lung Adenocarcinoma Successfully Treated With Osimertinib After Spontaneous Transformation to SCLC and Adenocarcinoma With Neuroendocrine Differentiation: Case Report. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100264.	0.6	1
6	Trimethoprim-sulfamethoxazole induced eosinophilic pneumonia: A case report. <i>Respiratory Medicine Case Reports</i> , 2022, 37, 101632.	0.2	1
7	Multiple organ infarction caused by aortic thrombus in a lung cancer patient with the BRAF mutation. <i>Respiratory Medicine Case Reports</i> , 2022, 36, 101608.	0.2	1
8	Exploratory Analysis Comparing Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blind, Phase 3 Study (CONSOLE). <i>Oncology and Therapy</i> , 2022, 10, 253-262.	1.0	9
9	Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: mortality and its prediction model. <i>Respiratory Research</i> , 2022, 23, 57.	1.4	18
10	Impact of antifibrotic therapy on lung cancer development in idiopathic pulmonary fibrosis. <i>Thorax</i> , 2022, 77, 727-730.	2.7	9
11	Topical Formulations of Propranolol for Infantile Hemangiomas: Characteristics of Formulations and Three Cases of Infants Administered Topical Propranolol Cream. <i>Chemical and Pharmaceutical Bulletin</i> , 2022, 70, 277-282.	0.6	2
12	Impact of end-of-life respiratory modalities on quality of dying and death and symptom relief in patients with interstitial lung disease: a multicenter descriptive cross-sectional study. <i>Respiratory Research</i> , 2022, 23, 79.	1.4	2
13	Efficacy and safety of propranolol cream in infantile hemangioma: A prospective pilot study. <i>Journal of Pharmacological Sciences</i> , 2022, 149, 60-65.	1.1	4
14	Effects of adding a neurokinin-1 receptor antagonist to 5Âµg olanzapine, a 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone for preventing carboplatin-induced nausea and vomiting: a propensity score-matched analysis. <i>BMC Cancer</i> , 2022, 22, 310.	1.1	0
15	CD109 on Dendritic Cells Regulates Airway Hyperreactivity and Eosinophilic Airway Inflammation. , 2022, , .		0
16	Combined Assessment of the GAP Index and Body Mass Index at Antifibrotic Therapy Initiation for Prognosis of Idiopathic Pulmonary Fibrosis. , 2022, , .		0
17	Acute Exacerbation of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Prognostic Factors and Mortality Prediction Model. , 2022, , .		0
18	Frequencies and Prognostic Factors of Acute Exacerbation of Systemic Autoimmune Disease-Related Interstitial Lung Diseases: A Retrospective Study. , 2022, , .		0

#	ARTICLE	IF	CITATIONS
19	Effects of long-acting muscarinic antagonists on promoting ciliary function in airway epithelium. <i>BMC Pulmonary Medicine</i> , 2022, 22, 186.	0.8	3
20	Standardised 3D-CT lung volumes for patients with idiopathic pulmonary fibrosis. <i>Respiratory Research</i> , 2022, 23, .	1.4	4
21	Chemotherapy for patients with advanced lung cancer with interstitial lung disease: a prospective observational study. <i>Therapeutic Advances in Chronic Disease</i> , 2022, 13, 204062232211083.	1.1	2
22	Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer. <i>Clinical and Translational Oncology</i> , 2021, 23, 418-423.	1.2	31
23	Clinical evaluation of drug-drug interactions between the cytochrome P450 substrates selexipag and clopidogrel in Japanese volunteers. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1903-1911.	1.1	0
24	Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis/dermatomyositis-associated <scp>ILD</scp>: A randomized, open-label trial. <i>Respirology</i> , 2021, 26, 370-377.	1.3	24
25	Quality of dying and death in patients with interstitial lung disease compared with lung cancer: an observational study. <i>Thorax</i> , 2021, 76, 248-255.	2.7	11
26	Subcutaneous injection of interferon gamma therapy could be useful for anti-IFN- γ autoantibody associated disseminated nontuberculous mycobacterial infection. <i>Journal of Infection and Chemotherapy</i> , 2021, 27, 373-378.	0.8	11
27	Erlotinib and bevacizumab in elderly patients ≥ 75 years old with non-small cell lung cancer harboring epidermal growth factor receptor mutations. <i>Investigational New Drugs</i> , 2021, 39, 210-216.	1.2	4
28	Cause of mortality and sarcopenia in patients with idiopathic pulmonary fibrosis receiving <scp>antifibrotic</scp> therapy. <i>Respirology</i> , 2021, 26, 171-179.	1.3	24
29	Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib. <i>BMC Cancer</i> , 2021, 21, 57.	1.1	3
30	Verification of a cocktail approach for quantitative drug-drug interaction assessment: a comparative analysis between the results of a single drug and a cocktail drug. <i>Xenobiotica</i> , 2021, 51, 404-412.	0.5	2
31	Predictors for bronchoalveolar lavage recovery failure in diffuse parenchymal lung disease. <i>Scientific Reports</i> , 2021, 11, 1682.	1.6	5
32	Cluster analysis-based clinical phenotypes of idiopathic interstitial pneumonias: associations with acute exacerbation and overall survival. <i>BMC Pulmonary Medicine</i> , 2021, 21, 63.	0.8	4
33	Conventional type 2 lung dendritic cells are potent inducers of follicular helper T cells in the asthmatic lung. <i>Allergy International</i> , 2021, 70, 351-359.	1.4	13
34	Gremlin-1 for the Differential Diagnosis of Idiopathic Pulmonary Fibrosis Versus Other Interstitial Lung Diseases: A Clinical and Pathophysiological Analysis. <i>Lung</i> , 2021, 199, 289-298.	1.4	11
35	Simple method for detecting idiopathic interstitial pneumonias by measuring vertical lung length on chest X-ray. <i>Scientific Reports</i> , 2021, 11, 7669.	1.6	2
36	Prognostic and Clinical Value of Cluster Analysis in Idiopathic Pleuroparenchymal Fibroelastosis Phenotypes. <i>Journal of Clinical Medicine</i> , 2021, 10, 1498.	1.0	11

#	ARTICLE	IF	CITATIONS
37	Prognostic classification in acute exacerbation of idiopathic pulmonary fibrosis: a multicentre retrospective cohort study. <i>Scientific Reports</i> , 2021, 11, 9120.	1.6	9
38	Analysis of Serum Angiopoietin-1 and -2 Concentrations in Patients with Pulmonary Hypertension. , 2021, , .		0
39	Examination of Pleural Fibrosis Model Mice Induced by Simultaneous Intrapleural Administration of Bleomycin and Carbon and Examine the Therapeutic Effect of Metformin. , 2021, , .		0
40	Impaired Autophagy Exacerbates Eosinophilic Airway Inflammation in Murine Model of Obesity Asthma. , 2021, , .		0
41	Long Acting Muscarinic Antagonists Promote Ciliary Function in Airway Epithelium. , 2021, , .		0
42	Prediction of the Area under the Curve Using Limited-Point Blood Sampling in a Cocktail Study to Assess Multiple CYP Activities. <i>Biological and Pharmaceutical Bulletin</i> , 2021, 44, 762-770.	0.6	0
43	Prognostic significance of peripheral blood monocyte and neutrophil counts in rheumatoid arthritis-associated interstitial lung disease. <i>Respiratory Medicine</i> , 2021, 182, 106420.	1.3	12
44	Molecular Pathogenesis of Pulmonary Fibrosis, with Focus on Pathways Related to TGF- β 2 and the Ubiquitin-Proteasome Pathway. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6107.	1.8	55
45	Serum S100A8 and S100A9 as prognostic biomarkers in acute exacerbation of idiopathic pulmonary fibrosis. <i>Respiratory Investigation</i> , 2021, 59, 827-836.	0.9	13
46	Clinical Significance of Interstitial Lung Disease and Its Acute Exacerbation in Microscopic Polyangiitis. <i>Chest</i> , 2021, 159, 2334-2345.	0.4	18
47	Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials. <i>BMC Cancer</i> , 2021, 21, 832.	1.1	1
48	Comparative assessment of NOIR-SS and ddPCR for ctDNA detection of EGFR L858R mutations in advanced L858R-positive lung adenocarcinomas. <i>Scientific Reports</i> , 2021, 11, 14999.	1.6	5
49	Serum tumor markers for the prediction of concordance between genomic profiles from liquid and tissue biopsy in patients with advanced lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2021, 10, 3236-3250.	1.3	4
50	Omeprazole suppresses endothelial calcium response and eNOS Ser1177 phosphorylation in porcine aortic endothelial cells. <i>Molecular Biology Reports</i> , 2021, 48, 5503-5511.	1.0	4
51	Clinical Significance of Cold-Inducible RNA-Binding Protein in Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2021, 160, 2149-2157.	0.4	7
52	Diagnostic and prognostic significance of serum angiopoietin-1 and -2 concentrations in patients with pulmonary hypertension. <i>Scientific Reports</i> , 2021, 11, 15502.	1.6	4
53	Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study. <i>BMC Pulmonary Medicine</i> , 2021, 21, 221.	0.8	15
54	Combined assessment of the GAP index and body mass index at antifibrotic therapy initiation for prognosis of idiopathic pulmonary fibrosis. <i>Scientific Reports</i> , 2021, 11, 18579.	1.6	4

#	ARTICLE	IF	CITATIONS
55	Pneumothorax in Patients with Idiopathic Pleuroparenchymal Fibroelastosis: Incidence, Clinical Features, and Risk Factors. <i>Respiration</i> , 2021, 100, 19-26.	1.2	16
56	Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with uncommon histology: a propensity-score-matched analysis. <i>BMC Pulmonary Medicine</i> , 2021, 21, 309.	0.8	2
57	Transient leukocytopenia following combination therapy for COVID-19. <i>Respiratory Investigation</i> , 2021, 60, 158-158.	0.9	3
58	MET Amplification and Efficacy of Nivolumab in Patients With NSCLC. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100239.	0.6	4
59	Radiological pleuroparenchymal fibroelastosis-like lesion in idiopathic interstitial pneumonias. <i>Respiratory Research</i> , 2021, 22, 290.	1.4	11
60	Response. <i>Chest</i> , 2021, 160, e683-e685.	0.4	0
61	Prophylactic granulocyte-colony stimulating factor in patients with lung neuroendocrine carcinoma receiving platinum agents plus etoposide. <i>Cancer Treatment and Research Communications</i> , 2021, 29, 100493.	0.7	1
62	Association of the Geriatric Nutritional Risk Index with the survival of patients with non-small-cell lung cancer after platinum-based chemotherapy. <i>BMC Pulmonary Medicine</i> , 2021, 21, 409.	0.8	9
63	Clinical significance of serum S100 calcium-binding protein A4 in idiopathic pulmonary fibrosis. <i>Respirology</i> , 2020, 25, 743-749.	1.3	22
64	Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 141, 21-31.	0.9	20
65	Paraneoplastic Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome Should Be Treated with Low-dose Prednisolone During Pembrolizumab Therapy: The Authors' Reply. <i>Internal Medicine</i> , 2020, 59, 599-599.	0.3	0
66	Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis. <i>Therapeutic Advances in Respiratory Disease</i> , 2020, 14, 175346662095378.	1.0	3
67	Disease course and prognosis of pleuroparenchymal fibroelastosis compared with idiopathic pulmonary fibrosis. <i>Respiratory Medicine</i> , 2020, 171, 106078.	1.3	23
68	Palliative Care for Idiopathic Pulmonary Fibrosis Patients: Pulmonary Physicians' View. <i>Journal of Pain and Symptom Management</i> , 2020, 60, 933-940.	0.6	20
69	Propensity score analysis of overall survival between first- and second-generation EGFR TKIs using real-world data. <i>Cancer Science</i> , 2020, 111, 3705-3713.	1.7	10
70	Development of a novel T cell-oriented vaccine using CTL/Th hybrid epitope long peptide and biodegradable microparticles, against an intracellular bacterium. <i>Microbiology and Immunology</i> , 2020, 64, 666-678.	0.7	1
71	Influenza A virus enhances ciliary activity and mucociliary clearance via TLR3 in airway epithelium. <i>Respiratory Research</i> , 2020, 21, 282.	1.4	14
72	Incidence and Clinical Features of Pneumothorax in Patients with Idiopathic Pleuroparenchymal Fibroelastosis. , 2020, , .		0

#	ARTICLE	IF	CITATIONS
73	Evaluation of Programmed Death Ligand 1 (<i>PD-L1</i>) Gene Amplification and Response to Nivolumab Monotherapy in Non-â€‘small Cell Lung Cancer. <i>JAMA Network Open</i> , 2020, 3, e2011818.	2.8	26
74	14-3-3 β Protein: A Novel Serum Biomarker for Predicting Prognosis in Idiopathic Pulmonary Fibrosis. , 2020, , .		0
75	Mac-2 Binding Protein Glycosylation Isomer in Patients with Chronic Pulmonary Aspergillosis. , 2020, , .		0
76	Conventional Type 2 Lung Dendritic Cells in Asthma Mouse Model Significantly Induce Follicular Helper T Cells Than Conventional Type 1. , 2020, , .		0
77	Development of a Novel T-Cell-Oriented Vaccine, Which Is Composed of Biodegradable Microparticles and T-Cell-Hybrid Epitope Long Peptide, Against Intracellular Bacteria. , 2020, , .		0
78	Leucine-Rich Î±2-Glycoprotein as a Potential Biomarker for Immune-related Colitis After Anti-â€‘PD-L1 Therapy: A Report of a Case Series. <i>Clinical Lung Cancer</i> , 2020, 21, e516-e522.	1.1	4
79	CD200 and CD200R1 are differentially expressed and have differential prognostic roles in non-small cell lung cancer. <i>Oncolmmunology</i> , 2020, 9, 1746554.	2.1	19
80	Acute exacerbation of unclassifiable idiopathic interstitial pneumonia: comparison with idiopathic pulmonary fibrosis. <i>Therapeutic Advances in Respiratory Disease</i> , 2020, 14, 175346662093577.	1.0	13
81	Assessment of Immune-Related Interstitial Lung Disease in Patients With NSCLC Treated with Immune Checkpoint Inhibitors: A Multicenter Prospective Study. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1317-1327.	0.5	46
82	Pneumothorax in connective tissue disease-associated interstitial lung disease. <i>PLoS ONE</i> , 2020, 15, e0235624.	1.1	14
83	Clinical Outcomes of Anti-programmed Death-1 Antibody-â€‘Related Pneumonitis in Patients with Non-Small Cell Lung Cancer. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 570-578.	0.3	8
84	Pulse oximetric saturation to fraction of inspired oxygen (SpO ₂ /FIO ₂) ratio 24 hours after high-flow nasal cannula (HFNC) initiation is a good predictor of HFNC therapy in patients with acute exacerbation of interstitial lung disease. <i>Therapeutic Advances in Respiratory Disease</i> , 2020, 14, 175346662090632.	1.0	5
85	CD248 and integrin alpha-8 are candidate markers for differentiating lung fibroblast subtypes. <i>BMC Pulmonary Medicine</i> , 2020, 20, 21.	0.8	23
86	Intravoxel incoherent motion magnetic resonance imaging for predicting the long-term efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer. <i>Lung Cancer</i> , 2020, 143, 47-54.	0.9	6
87	Simultaneous LC-MS analysis of plasma concentrations of sildenafil, tadalafil, bosentan, ambrisentan, and macitentan in patients with pulmonary arterial hypertension. <i>Die Pharmazie</i> , 2020, 75, 236-239.	0.3	6
88	Body composition changes successfully classify prognosis in patients with mycobacterium avium complex lung disease. <i>Journal of Infection</i> , 2019, 79, 341-348.	1.7	9
89	Simultaneous Occurrence of Sarcoidosis and Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis in a Patient with Lung Cancer. <i>Internal Medicine</i> , 2019, 58, 3299-3304.	0.3	8
90	Multicenter, placebo-â€‘controlled, double-â€‘blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy-â€‘induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. <i>Cancer</i> , 2019, 125, 4076-4083.	2.0	11

#	ARTICLE	IF	CITATIONS
91	Heterogeneity analysis of PD-L1 expression and copy number status in EBUS-TBNA biopsy specimens of non-small cell lung cancer: Comparative assessment of primary and metastatic sites. <i>Lung Cancer</i> , 2019, 134, 202-209.	0.9	35
92	<p>Clinical features of three-dimensional computed tomography-based radiologic phenotypes of chronic obstructive pulmonary disease</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 1333-1342.	0.9	4
93	Ease of Taking and Palatability of Fixed-Dose Orally Disintegrating Mitiglinide/Voglibose Tablets. <i>Chemical and Pharmaceutical Bulletin</i> , 2019, 67, 540-545.	0.6	3
94	Analysis of serum adiponectin and leptin in patients with acute exacerbation of idiopathic pulmonary fibrosis. <i>Scientific Reports</i> , 2019, 9, 10484.	1.6	20
95	Prognostic factors for primary Sjögren's syndrome-associated interstitial lung diseases. <i>Respiratory Medicine</i> , 2019, 159, 105811.	1.3	22
96	Effect of rifampicin and clarithromycin on the CYP3A activity in patients with Mycobacterium avium complex. <i>Journal of Thoracic Disease</i> , 2019, 11, 3814-3821.	0.6	8
97	Transient Laterality of Cerebral Oxygenation Changes in Response to Head-of-Bed Manipulation in Acute Ischemic Stroke. <i>Journal of Clinical Medicine</i> , 2019, 8, 1739.	1.0	0
98	The Prediction of the Area under the Curve and Clearance of Midazolam from Single-Point Plasma Concentration and Urinary Excretion in Healthy Volunteers. <i>Biological and Pharmaceutical Bulletin</i> , 2019, 42, 1590-1595.	0.6	2
99	Synchronous Occurrence of Bazex Syndrome and Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome in a Patient with Lung Cancer. <i>Internal Medicine</i> , 2019, 58, 3267-3271.	0.3	5
100	<p>Effect of PD-1 inhibitor on exhaled nitric oxide and pulmonary function in non-small cell lung cancer patients with and without COPD</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 1867-1877.	0.9	12
101	<p>Once-daily fluticasone furoate/vilanterol combination versus twice-daily budesonide/formoterol combination in the treatment of controlled stable asthma: a randomized crossover trial</p>. <i>Journal of Asthma and Allergy</i> , 2019, Volume 12, 253-261.	1.5	7
102	Prognostic impact of an early marginal decline in forced vital capacity in idiopathic pulmonary fibrosis patients treated with pirfenidone. <i>Respiratory Investigation</i> , 2019, 57, 552-560.	0.9	7
103	Correlation of the modified Medical Research Council dyspnea scale with airway structure assessed by three-dimensional CT in patients with chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2019, 146, 76-80.	1.3	8
104	Efficacy of Glucocorticoids and Calcineurin Inhibitors for Anti-aminoacyl-tRNA Synthetase Antibodyâ€“positive Polymyositis/dermatomyositisâ€“associated Interstitial Lung Disease: A Propensity Scoreâ€“matched Analysis. <i>Journal of Rheumatology</i> , 2019, 46, 509-517.	1.0	18
105	Physiological and morphological differences of airways between COPD and asthmaâ€“COPD overlap. <i>Scientific Reports</i> , 2019, 9, 7818.	1.6	27
106	Frequency and clinical relevance of anti-cyclic citrullinated peptide antibody in idiopathic interstitial pneumonias. <i>Respiratory Medicine</i> , 2019, 154, 102-108.	1.3	11
107	Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD. <i>Rheumatology</i> , 2019, 58, 2143-2152.	0.9	56
108	Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 147-153.	1.1	17

#	ARTICLE	IF	CITATIONS
109	Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibodyâ€“positive Dermatomyositis-associated Interstitial Lung Disease. <i>Journal of Rheumatology</i> , 2019, 46, 935-942.	1.0	28
110	Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype. <i>Journal of Pharmacological Sciences</i> , 2019, 139, 361-366.	1.1	12
111	Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma. <i>Investigational New Drugs</i> , 2019, 37, 531-537.	1.2	3
112	Preparation of Cocoa Powder-Containing Orally Disintegrating Tablets of Rebamipide (Rebamipide) Tj ETQqO 0 0 rgBT /Overlock 10 Tf 50 67, 112-119.	0.6	13
113	Efficacy of corticosteroid and intravenous cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis: A propensity scoreâ€“matched analysis. <i>Respirology</i> , 2019, 24, 792-798.	1.3	25
114	The Relationship Between the Modified Medical Research Council (mMRC) Dyspnea Scale and Airway Structure Assessed by Three-Dimensional CT in Patients with Chronic Obstructive Pulmonary Disease. , 2019, , .		0
115	Survival Benefit of Corticosteroid and Intravenous Cyclophosphamide Therapy in Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Propensity Score-Matched Analysis. , 2019, , .		0
116	Clinical Utility of Serum S100 Calcium Binding Protein A4 in Idiopathic Pulmonary Fibrosis. , 2019, , .		0
117	Prognostic Significance of Pneumothorax in Patients with Connective Tissue Disease Associated Interstitial Lung Diseases. , 2019, , .		0
118	Macrophage Mannose Receptor CD206 Predicts Prognosis in Community-acquired Pneumonia. <i>Scientific Reports</i> , 2019, 9, 18750.	1.6	28
119	Differences in clinical features of acute exacerbation between connective tissue disease-associated interstitial pneumonia and idiopathic pulmonary fibrosis. <i>Chronic Respiratory Disease</i> , 2019, 16, 147997231880947.	1.0	25
120	Podoplaninâ€“positive myofibroblasts: a pathological hallmark of pleuroparenchymal fibroelastosis. <i>Histopathology</i> , 2018, 72, 1209-1215.	1.6	12
121	Distinctive characteristics and prognostic significance of interstitial pneumonia with autoimmune features in patients with chronic fibrosing interstitial pneumonia. <i>Respiratory Medicine</i> , 2018, 137, 167-175.	1.3	45
122	Neutrophil gelatinase-associated lipocalin in patients with sarcoidosis. <i>Respiratory Medicine</i> , 2018, 138, S20-S23.	1.3	5
123	Respiratory impedance is correlated with airway narrowing in asthma using threeâ€“dimensional computed tomography. <i>Clinical and Experimental Allergy</i> , 2018, 48, 278-287.	1.4	10
124	Heterogeneous MET gene copy number and EGFR mutation elicit discordant responses to crizotinib between primary and metastatic lesions in erlotinib-resistant lung adenocarcinoma. <i>Lung Cancer</i> , 2018, 124, 317-319.	0.9	6
125	Changes in gefitinib, erlotinib and osimertinib pharmacokinetics under various gastric pH levels following oral administration of omeprazole and vonoprazan in rats. <i>Xenobiotica</i> , 2018, 48, 1106-1112.	0.5	16
126	Body sizeâ€“adjusted dose analysis of pirfenidone in patients with interstitial pneumonia. <i>Respirology</i> , 2018, 23, 318-324.	1.3	27

#	ARTICLE	IF	CITATIONS
127	The prognostic significance of pneumothorax in patients with idiopathic pulmonary fibrosis. <i>Respirology</i> , 2018, 23, 519-525.	1.3	35
128	Distinct profile and prognostic impact of body composition changes in idiopathic pulmonary fibrosis and idiopathic pleuroparenchymal fibroelastosis. <i>Scientific Reports</i> , 2018, 8, 14074.	1.6	66
129	<i>In Vivo</i> Drug Dissolution in Human Oral Cavity from Orally Disintegrating Tablet and Comparability with <i>In Vitro</i> Testing. <i>Chemical and Pharmaceutical Bulletin</i> , 2018, 66, 999-1005.	0.6	4
130	IL-17A Attenuates IFN- γ Expression by Inducing Suppressor of Cytokine Signaling Expression in Airway Epithelium. <i>Journal of Immunology</i> , 2018, 201, 2392-2402.	0.4	25
131	Macrophage mannose receptor, CD206, predict prognosis in patients with pulmonary tuberculosis. <i>Scientific Reports</i> , 2018, 8, 13129.	1.6	50
132	Prophylactic aprepitant is better than salvage for carboplatin-based chemotherapy: a propensity score-matched analysis. <i>Medical Oncology</i> , 2018, 35, 139.	1.2	6
133	Low-dose Fluticasone Propionate in Combination With Salmeterol in Patients With Chronic Obstructive Pulmonary Disease. <i>Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine</i> , 2018, 12, 117954841877170.	0.5	0
134	Clinical significance of myeloperoxidase-anti-neutrophil cytoplasmic antibody in idiopathic interstitial pneumonias. <i>PLoS ONE</i> , 2018, 13, e0199659.	1.1	47
135	Changes in pulmonary endothelial cell properties during bleomycin-induced pulmonary fibrosis. <i>Respiratory Research</i> , 2018, 19, 127.	1.4	30
136	Inhibiting Skp2 E3 Ligase Suppresses Bleomycin-Induced Pulmonary Fibrosis. <i>International Journal of Molecular Sciences</i> , 2018, 19, 474.	1.8	16
137	LTBP2 is secreted from lung myofibroblasts and is a potential biomarker for idiopathic pulmonary fibrosis. <i>Clinical Science</i> , 2018, 132, 1565-1580.	1.8	37
138	An Acquired Epidermal Growth Factor Receptor T790M Mutation after the Addition of Bevacizumab to Preceding Erlotinib Monotherapy in a Lung Cancer Patient with Leptomeningeal Metastases. <i>Internal Medicine</i> , 2018, 57, 3423-3427.	0.3	3
139	Differences in airway structural changes assessed by 3-dimensional computed tomography in asthma and asthma-chronic obstructive pulmonary disease overlap. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 121, 704-710.e1.	0.5	10
140	Prognostic evaluation of serum ferritin in acute exacerbation of idiopathic pulmonary fibrosis. <i>Clinical Respiratory Journal</i> , 2018, 12, 2378-2389.	0.6	31
141	Utility of serum <i>Aspergillus</i> -galactomannan antigen to evaluate the risk of severe acute exacerbation in chronic obstructive pulmonary disease. <i>PLoS ONE</i> , 2018, 13, e0198479.	1.1	7
142	Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study. <i>Medical Oncology</i> , 2018, 35, 108.	1.2	3
143	Relationship between gastric pH and plasma concentrations of gefitinib, erlotinib and osimertinib after oral administrations in rat. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO2-14-25.	0.0	0
144	Evaluation of palatability of cocoa-flavored gummi drug of aripiprazole developed from commercially available tablets. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO2-15-15.	0.0	0

#	ARTICLE	IF	CITATIONS
145	Topical Propranolol Treatment for Infantile Hemangioma; A Case Series. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO2-15-14.	0.0	0
146	Evaluation of urinary desmosines as a noninvasive diagnostic biomarker in patients with idiopathic pleuroparenchymal fibroelastosis (PPFE). <i>Respiratory Medicine</i> , 2017, 123, 63-70.	1.3	17
147	Japanese herbal medicine-induced pneumonitis: A review of 73 patients. <i>Respiratory Investigation</i> , 2017, 55, 138-144.	0.9	35
148	Predictive factors for long-term outcome in polymyositis/dermatomyositis-associated interstitial lung diseases. <i>Respiratory Investigation</i> , 2017, 55, 130-137.	0.9	37
149	Antiemetic therapy for non-anthracycline and cyclophosphamide moderately emetogenic chemotherapy. <i>Medical Oncology</i> , 2017, 34, 77.	1.2	5
150	Respiratory impedance is correlated with morphological changes in the lungs on three-dimensional CT in patients with COPD. <i>Scientific Reports</i> , 2017, 7, 41709.	1.6	30
151	Distinct prognostic roles and heterogeneity of <i>TTF1</i> copy number and <i>TTF1</i> protein expression in non-small cell lung cancer. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 570-581.	1.5	12
152	Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy. <i>Respiratory Medicine Case Reports</i> , 2017, 20, 160-163.	0.2	14
153	Persistent impairment on spirometry in chronic eosinophilic pneumonia. <i>Annals of Allergy, Asthma and Immunology</i> , 2017, 119, 422-428.e2.	0.5	16
154	Relationship between fraction of exhaled nitric oxide and airway morphology assessed by three-dimensional CT analysis in asthma. <i>Scientific Reports</i> , 2017, 7, 10187.	1.6	25
155	Clinical Utility of YKL-40 in Polymyositis/dermatomyositis-associated Interstitial Lung Disease. <i>Journal of Rheumatology</i> , 2017, 44, 1394-1401.	1.0	37
156	Characterization of V&Eset and immunoglobulin domain containing 1 exerting a tumor suppressor function in gastric, lung, and esophageal cancer cells. <i>Cancer Science</i> , 2017, 108, 1701-1714.	1.7	13
157	Clinical diagnosis of idiopathic pleuroparenchymal fibroelastosis: A retrospective multicenter study. <i>Respiratory Medicine</i> , 2017, 133, 1-5.	1.3	89
158	Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease. <i>Arthritis Research and Therapy</i> , 2017, 19, 9.	1.6	46
159	Multifaceted evaluation in the pathogenesis of sarcoidosis. <i>The Japanese Journal of Sarcoidosis and Other Granulomatous Disorders</i> , 2017, 37, 15-18.	0.1	0
160	Synchronous Duodenal Cancer and Lung Cancer Harboring an Epidermal Growth Factor Receptor Mutation Treated with Erlotinib and Oral Fluoropyrimidine. <i>Internal Medicine</i> , 2017, 56, 2367-2371.	0.3	3
161	Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer. <i>Oncotarget</i> , 2017, 8, 8738-8751.	0.8	129
162	Radiologic pleuroparenchymal fibroelastosis-like lesion in connective tissue disease-related interstitial lung disease. <i>PLoS ONE</i> , 2017, 12, e0180283.	1.1	60

#	ARTICLE	IF	CITATIONS
163	Pirfenidone for primary Sjögren's syndrome-related fibrotic interstitial pneumonia. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2017, 34, 91-96.	0.2	2
164	Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer. <i>Oncotarget</i> , 2016, 7, 32113-32128.	0.8	100
165	Changes in cross-sectional area of pulmonary vessels on chest computed tomography after chemotherapy in patients with advanced non-squamous non-small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 1011-1018.	1.1	2
166	Sequential addition of aprepitant in patients receiving carboplatin-based chemotherapy. <i>Medical Oncology</i> , 2016, 33, 65.	1.2	1
167	Increased levels of serum <i>Wisteria floribunda</i> agglutinin-positive Mac-2 binding protein in idiopathic pulmonary fibrosis. <i>Respiratory Medicine</i> , 2016, 115, 46-52.	1.3	26
168	Low forced vital capacity predicts cytotoxic chemotherapy-associated acute exacerbation of interstitial lung disease in patients with lung cancer. <i>Lung Cancer</i> , 2016, 96, 63-67.	0.9	44
169	Nonspecific interstitial pneumonia preceding diagnosis of collagen vascular disease. <i>Respiratory Medicine</i> , 2016, 117, 40-47.	1.3	32
170	Non-invasive evaluation of pulmonary arterial blood flow and wall shear stress in pulmonary arterial hypertension with 3D phase contrast magnetic resonance imaging. <i>SpringerPlus</i> , 2016, 5, 1071.	1.2	31
171	Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil+Bosentan and Sildenafil+Ambrisentan Combination Therapies for Pulmonary Hypertension. <i>Clinical and Translational Science</i> , 2016, 9, 29-35.	1.5	7
172	Step-down treatment from medium-dosage of budesonide/formoterol in controlled asthma. <i>Respiratory Medicine</i> , 2016, 119, 1-6.	1.3	14
173	Soluble hemoglobin scavenger receptor CD163 (sCD163) predicts mortality of community-acquired pneumonia. <i>Journal of Infection</i> , 2016, 73, 375-377.	1.7	5
174	Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease. <i>Respiratory Medicine</i> , 2016, 121, 91-99.	1.3	121
175	Clinical Significance of Forced Oscillation Technique for Evaluation of Small Airway Disease in Interstitial Lung Diseases. <i>Lung</i> , 2016, 194, 975-983.	1.4	20
176	Impact of angiotensin-1 and -2 on clinical course of idiopathic pulmonary fibrosis. <i>Respiratory Medicine</i> , 2016, 114, 18-26.	1.3	10
177	Continuation maintenance therapy with S-1 in chemotherapy-naïve patients with advanced squamous cell lung cancer. <i>Investigational New Drugs</i> , 2016, 34, 490-496.	1.2	8
178	Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer. <i>European Journal of Cancer</i> , 2016, 58, 30-37.	1.3	29
179	Clinical Implication of Proteinase-3-antineutrophil Cytoplasmic Antibody in Patients with Idiopathic Interstitial Pneumonias. <i>Lung</i> , 2016, 194, 235-242.	1.4	33
180	Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy in non-squamous non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, e20504-e20504.	0.8	0

#	ARTICLE	IF	CITATIONS
181	Final analysis of erlotinib monotherapy for elderly patients with non-small-cell lung cancer harboring activating EGFR mutations.. Journal of Clinical Oncology, 2016, 34, e20566-e20566.	0.8	0
182	A case of treatment with voriconazole for chronic progressive pulmonary aspergillosis in a patient receiving tacrolimus for dermatomyositis-associated interstitial lung disease. Respiratory Medicine Case Reports, 2015, 16, 163-165.	0.2	6
183	Clinicopathological and Survival Analysis of Japanese Patients with Resected Non-Small-Cell Lung Cancer Harboring NKX2-1, SETDB1, MET, HER2, SOX2, FGFR1, or PIK3CA Gene Amplification. Journal of Thoracic Oncology, 2015, 10, 1590-1600.	0.5	40
184	Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer. Lung Cancer, 2015, 90, 410-416.	0.9	27
185	Nontypeable Haemophilus influenzae exploits the interaction between protein-E and vitronectin for the adherence and invasion to bronchial epithelial cells. BMC Microbiology, 2015, 15, 263.	1.3	20
186	Effects of indacaterol versus tiotropium on respiratory mechanics assessed by the forced oscillation technique in patients with chronic obstructive pulmonary disease. International Journal of COPD, 2015, 10, 1139.	0.9	9
187	Prognostic Significance of Anti-Aminoacyl-tRNA Synthetase Antibodies in Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease: A Retrospective Case Control Study. PLoS ONE, 2015, 10, e0120313.	1.1	74
188	Cumulative Incidence and Predictors of Progression in Corticosteroid-Na ⁺ ve Patients with Sarcoidosis. PLoS ONE, 2015, 10, e0143371.	1.1	15
189	Phase II study of erlotinib in elderly patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations. Cancer Chemotherapy and Pharmacology, 2015, 76, 155-161.	1.1	34
190	Evaluation of antibody levels over 3years after 23-valent pneumococcal polysaccharide vaccination in patients with pulmonary diseases receiving steroids and immunosuppressive agents. Clinical Biochemistry, 2015, 48, 125-129.	0.8	5
191	Safety of topotecan monotherapy for relapsed small cell lung cancer patients with pre-existing interstitial lung disease. Cancer Chemotherapy and Pharmacology, 2015, 76, 499-505.	1.1	24
192	Treatment of acute exacerbation of idiopathic pulmonary fibrosis with direct hemoperfusion using a polymyxin B-immobilized fiber column improves survival. BMC Pulmonary Medicine, 2015, 15, 15.	0.8	66
193	A case of spontaneous regression of pulmonary mucosa-associated lymphoid tissue (MALT) type lymphoma with Sjögren's syndrome treated with methotrexate for rheumatoid arthritis. Respiratory Medicine Case Reports, 2015, 15, 4-6.	0.2	3
194	Efficacy of short-term prednisolone treatment in patients with chronic eosinophilic pneumonia. European Respiratory Journal, 2015, 45, 1624-1631.	3.1	32
195	Indacaterol and tiotropium combination therapy in patients with chronic obstructive pulmonary disease. Pulmonary Pharmacology and Therapeutics, 2015, 30, 11-15.	1.1	6
196	Synergistic Proinflammatory Responses by IL-17A and Toll-Like Receptor 3 in Human Airway Epithelial Cells. PLoS ONE, 2015, 10, e0139491.	1.1	12
197	Impact of Preexisting Interstitial Lung Disease on Acute, Extensive Radiation Pneumonitis: Retrospective Analysis of Patients with Lung Cancer. PLoS ONE, 2015, 10, e0140437.	1.1	53
198	Switching from salmeterol/fluticasone to formoterol/budesonide combinations improves peripheral airway/alveolar inflammation in asthma. Pulmonary Pharmacology and Therapeutics, 2014, 27, 52-56.	1.1	10

#	ARTICLE	IF	CITATIONS
199	Plasma connective tissue growth factor levels as potential biomarkers of airway obstruction in patients with asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2014, 113, 295-300.	0.5	10
200	Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy. <i>Lung Cancer</i> , 2014, 84, 259-264.	0.9	56
201	Usual Interstitial Pneumonia Preceding Collagen Vascular Disease: A Retrospective Case Control Study of Patients Initially Diagnosed with Idiopathic Pulmonary Fibrosis. <i>PLoS ONE</i> , 2014, 9, e94775.	1.1	61
202	Prognostic Factors for Myositis-Associated Interstitial Lung Disease. <i>PLoS ONE</i> , 2014, 9, e98824.	1.1	131
203	Retrospective evaluation of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer with stereotactic radiotherapy: A multi-institutional study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7591-7591.	0.8	1
204	Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 445-452.	1.1	12
205	Chronological Effects of Rifampicin Discontinuation on Cytochrome P450 Activity in Healthy Japanese Volunteers, Using the Cocktail Method. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 702-708.	2.3	31
206	Multidetector-row computed tomography assessment of adding budesonide/formoterol to tiotropium in patients with chronic obstructive pulmonary disease. <i>Pulmonary Pharmacology and Therapeutics</i> , 2013, 26, 336-341.	1.1	13
207	Alveolar nitric oxide concentration reflects peripheral airway obstruction in stable asthma. <i>Respirology</i> , 2013, 18, 522-527.	1.3	13
208	A randomized phase II trial comparing continuation maintenance therapy with pemetrexed and switch maintenance therapy with docetaxel after first-line therapy with carboplatin and pemetrexed in patients with advanced nonsquamous non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8038-8038.	0.8	0
209	Effect of Switching from Salmeterol/Fluticasone to Formoterol/Budesonide Combinations in Patients with Uncontrolled Asthma. <i>Allergology International</i> , 2012, 61, 323-329.	1.4	7
210	Novel Patch for Transdermal Administration of Morphine. <i>Journal of Pain and Symptom Management</i> , 2012, 44, 479-485.	0.6	8
211	Expression and Function of Multidrug Resistance Protein 1 and Multidrug Resistance-Associated Protein 1 in Lung Dendritic Cells From Aging Mice. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2012, 67, 1049-1055.	1.7	2
212	Impact of add-on pranlukast in stable asthma; the additive effect on peripheral airway inflammation. <i>Respiratory Medicine</i> , 2012, 106, 508-514.	1.3	17
213	Biweekly combination therapy with gemcitabine and carboplatin compared with gemcitabine monotherapy in elderly patients with advanced non-small-cell lung cancer: A randomized, phase-II study. <i>Lung Cancer</i> , 2012, 77, 550-555.	0.9	9
214	Expressions of multidrug resistance protein 1 and multidrug resistance-associated protein 1 in lung dendritic cells. <i>Life Sciences</i> , 2011, 89, 282-287.	2.0	5
215	Evaluation of Different Perfusion Durations in Direct Hemoperfusion with Polymyxin B-Immobilized Fiber Column Therapy for Acute Exacerbation of Interstitial Pneumonias. <i>Blood Purification</i> , 2011, 32, 75-81.	0.9	25
216	Phase II Study of Erlotinib as Third-line Monotherapy in Patients with Advanced Non-small-cell Lung Cancer without Epidermal Growth Factor Receptor Mutations. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 959-963.	0.6	17

#	ARTICLE	IF	CITATIONS
217	Pharmacokinetics and pharmacodynamics of low doses of midazolam administered intravenously and orally to healthy volunteers. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2010, 37, 290-295.	0.9	15
218	Effect of Thyroid Hormone on the Activity of CYP3A Enzyme in Humans. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 88-93.	1.0	22
219	Anti-endothelial Cell Antibodies in Patients With COPD. <i>Chest</i> , 2010, 138, 1303-1308.	0.4	56
220	Effects of Statins on the Pharmacokinetics of Midazolam in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 568-573.	1.0	15
221	Anti-cyclic citrullinated peptide antibodies in lung diseases associated with rheumatoid arthritis. <i>Clinical Biochemistry</i> , 2008, 41, 1074-1077.	0.8	67
222	Effects of ursodeoxycholic acid on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam in healthy volunteers. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2008, 377, 629-636.	1.4	14
223	Response to "The Unanswered Question: What Is the Determinant of S-1 Pharmacokinetics?" <i>Clinical Pharmacology and Therapeutics</i> , 2008, 84, 204-204.	2.3	0
224	The CYP2A6*4 Allele Is Determinant of S-1 Pharmacokinetics in Japanese Patients With Non-small-cell Lung Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 589-594.	2.3	35
225	Possible therapeutic effect of direct haemoperfusion with a polymyxin B immobilized fibre column (PMX- Δ DHP) on pulmonary oxygenation in acute exacerbations of interstitial pneumonia. <i>Respirology</i> , 2008, 13, 452-460.	1.3	570
226	Once-daily inhaled glucocorticosteroid administration in controlled asthma patients. <i>Pulmonary Pharmacology and Therapeutics</i> , 2008, 21, 663-667.	1.1	4
227	Use of the QuantiFERON-TB Gold test in Japanese patients with sarcoidosis. <i>Respiratory Medicine</i> , 2008, 102, 313-315.	1.3	35
228	Lung Dendritic Cells Have a Potent Capability to Induce Production of Immunoglobulin A. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2008, 38, 161-167.	1.4	28
229	Anti-Endothelial Cell Antibodies in Patients With Sarcoidosis. <i>Chest</i> , 2008, 133, 955-960.	0.4	17
230	Interstitial lung diseases associated with amyopathic dermatomyositis. <i>European Respiratory Journal</i> , 2006, 28, 1005-1012.	3.1	151
231	The loss of retinoic acid receptor α , β and alcohol dehydrogenase3 expression in non-small cell lung cancer. <i>Respirology</i> , 2003, 8, 302-309.	1.3	17
232	High expression of Cks1 in human non-small cell lung carcinomas. <i>Biochemical and Biophysical Research Communications</i> , 2003, 303, 978-984.	1.0	71
233	Correlation between 25-hydroxyvitamin D3 1 α -hydroxylase gene expression in alveolar macrophages and the activity of sarcoidosis. <i>American Journal of Medicine</i> , 2001, 110, 687-693.	0.6	77